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Introduction: Alzheimer’s disease (AD) is characterized by the deposition of tau and amyloid in the brain. Although
the core cerebrospinal fluid (CSF) AD biomarkers amyloid β peptide 1–42 (Aβ1–42), total tau (t-tau) and
phosphorylated tau 181 (p-tau181) show good diagnostic sensitivity and specificity, additional biomarkers that can
aid in preclinical diagnosis or better track disease progression are needed. Activation of the complement system,
a pivotal part of inflammation, occurs at very early stages in the AD brain. Therefore, CSF levels of complement
proteins that could be linked to cognitive and structural changes in AD may have diagnostic and prognostic value.
Methods: Using xMAP® technology based assays we measured complement 3 (C3) and factor H (FH) in the CSF of
110 controls (CN), 187 mild cognitive impairment (MCI) and 92 AD subjects of the AD Neuroimaging Initiative
(ADNI) at baseline. All ADNI participants underwent clinical follow-up at 12 month intervals and MCI subjects had
additional visits at 6 and 18 months. The association between CSF biomarkers and different outcome measures
were analyzed using Cox proportional hazard models (conversion from MCI to AD), logistic regression models
(classification of clinical groups) and mixed-effects models adjusted for age, gender, education, t-tau/Aβ1–42 and
APOE ε4 presence (baseline and longitudinal association between biomarkers and cognitive scores).
Results: Although no association was found between the complement proteins and clinical diagnosis or cognitive
measures, lower levels of C3 (β = −0.12, p = 0.041) and FH (β = −0.075, p = 0.041) were associated with faster
cognitive decline in MCI subjects as measured by the AD Assessment Scale-cognitive subscale (ADAS-Cog) test.
Furthermore, lower FH levels were associated with larger lateral ventricular volume (p = 0.024), which is indicative of
brain atrophy.
Conclusions: Our study confirms a lack of suitability of CSF C3 and FH as diagnostic biomarkers of AD, but points
to their modest potential as prognostic biomarkers and therapeutic targets in cognitively impaired patients.Introduction
Alzheimer’s disease (AD) affects an estimated 34 million
people worldwide, a number that is predicted to triple
by 2050 due to the aging population [1]. Despite inten-
sive research and the identification of several promising
drug candidates in preclinical studies, a neuroprotective
treatment remains a major unmet need. Possible reasons
for the failure of disease-modifying drug clinical trials* Correspondence: zhangj@u.washington.edu
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unless otherwise stated.include our inability to diagnose AD before substantial
neuronal damage has occurred, as well as track disease
progression and treatment response [2]. In this regard,
sensitive and specific biomarkers are urgently needed.
The cerebrospinal fluid (CSF) biomarkers amyloid β
peptide 1–42 (Aβ1–42), which correlates inversely with
plaque pathology, total tau (t-tau), which is hypothesized
to reflect neuroaxonal degeneration, and phosphorylated
tau (p-tau181), which may correlate with tangle pathology,
have recently been incorporated into the National Institute
on Aging guidelines for AD diagnosis [3]. With regard
to temporal dynamics, the decrease in CSF Aβ1–42
seems to be an early event, reaching a plateau before theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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thereafter. The increase in CSF tau occurs after Aβ1–42
changes, but still in the preclinical stage of the disease
and does not change appreciably over time in cogni-
tively impaired subjects [4,5]. Therefore, although these
core biomarkers show good sensitivity and specificity
for the diagnosis of AD, additional biomarkers that can
aid in the early diagnosis of dementia or can better track
disease progression will improve the design and inter-
pretation of clinical trials.
Neuroinflammation is generally recognized to be a
major component of AD [6]. However, whether it is a
cause, a contributing factor, or merely a consequence of
neurodegeneration is unclear. Clinical and experimental
evidence supports the involvement of inflammatory
changes in the early stages of AD before the appear-
ance of amyloid plaques [7], as well as in the progres-
sion of neurodegeneration [8]. If this is indeed the
case, biomarkers that reflect the inflammatory process
in AD hold promise for both early diagnosis and track-
ing of disease progression.
The complement system is a pivotal part of the immune
system and inflammatory processes. Depending on the
trigger, complement can be activated via the classical,
alternative, or lectin pathways. All three pathways cul-
minate in the formation of complement convertases,
which results in the proteolytic cleavage of complement 3
(C3) and, later in the cascade, complement 5. The resulting
active fragments act as proinflammatory and chemotactic
anaphylatoxins, opsonins allowing phagocytosis, or anchors
for the assembly of the membrane attack complex. The
complement system is kept under tight control by sol-
uble and membrane-bound regulators, including factor
H (FH), which inhibits C3 convertases in the alternative
pathway, and complement 1 inhibitor, which inhibits
several proteases of the classical and lectin pathways
[9]. The final outcome therefore depends on the balance
between complement activation and inhibition, and dys-
regulation of this balance may contribute to neuroin-
flammation and disease [10]. As expected, complement
activation has been shown to occur in the AD brain [9],
even at very early stages of the disease [11]. Further-
more, genome-wide association studies have identified
AD-associated variants at the complement receptor 1
gene [12,13], which correlate with a greater Aβ plaque bur-
den and age-related cognitive decline [14]. Polymorphisms
in the FH gene have also been linked to susceptibility to
AD [15], although there are conflicting reports [16].
In a previous cross-sectional study, we found that CSF
levels of C3 and FH were significantly increased in AD
patients compared with controls (CN) and that the in-
crease correlated significantly with lower Mini-Mental
State Examination (MMSE) scores in AD patients. In the
current study, we attempt to validate these observationsin a large, independent cohort of well-characterized
subjects. In addition, we extend the previous analysis
by including patients diagnosed with mild cognitive
impairment (MCI) and by analyzing additional clinical
and neuroimaging data. Finally, we explore the prog-
nostic potential of CSF C3 and FH levels by analyzing
longitudinally collected clinical data.
Methods
Subjects
Data used in the current study were downloaded on 27
July 2013 from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database [17]. Ethics approval was ob-
tained for each institution involved (see Acknowledgements
and Additional file 1). The ADNI is conducted according
to Good Clinical Practice guidelines, the Declaration of
Helsinki, US 21CFR Part 50 – Protection of Human
Subjects and Part 56 – Institutional Review Boards,
and pursuant to state and federal Health Insurance
Portability and Accountability Act regulations. Written
informed consent is obtained from all subjects and/or
authorized representatives and study partners before
protocol-specific procedures are carried out. Institutional
review boards were constituted according to applicable
State and Federal requirements for each participating lo-
cation. The protocols were submitted to the appropriate
boards and their written unconditional approval obtained
and submitted to Regulatory Affairs at the ADNI Co-
ordinating Center prior to commencement of the study.
The ADNI Coordinating Center supplied relevant data
for investigators to submit to their hospital/university/
independent institutional review boards for protocol re-
view and approval. Verification of institutional review
board unconditional approval of the protocol and the
written informed consent statement with written infor-
mation to be given to the participants and/or their au-
thorized representatives and the study partners were
transmitted and validated by the ADNI Coordinating
Center in order to obtain approval for shipment of study
supplies to study sites. The ADNI has previously been
described extensively [18]. Criteria for the different diagnos-
tic groups can be found in the ADNI procedures manual
[19] (see also Additional file 2). In the current study,
389 ADNI 1 [20] subjects (110 CN, 187 MCI subjects and
92 AD subjects) had C3, FH, Aβ1–42, t-tau and p-tau181
measured in their CSF samples at baseline.
Clinical assessment and cognitive profile
The same neuropsychological testing battery was applied
to all subjects in the ADNI, with visits scheduled every
12 months, except for the MCI subjects who had additional
visits at 6 and 18 months. Tests included the MMSE, the
Alzheimer’s Disease Assessment Scale – cognitive subscale
(ADAS-Cog), the clock drawing test, the Rey Auditory
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category fluency, the trail-making test, the digit symbol
substitution test, the Boston naming test and the logical
memory test. Finally, we further characterized the cogni-
tive profile of each subject using the summary composite
executive function and memory measures developed by
Gibbons and colleagues [21] and Crane and colleagues
[22]. These measures summarize into a score factors from
different tests that belong to the same cognitive domain,
giving each test a specific loading and accounting for
the difficulty of the different variations of the tests; for
example, the different word lists available for the Rey
Auditory Verbal Learning Test.
Cerebrospinal fluid sample collection and analysis
CSF samples were obtained in the morning after an
overnight fast at ADNI baseline visits. Lumbar puncture
was performed with a 20-gauge or 24-gauge spinal needle
as described previously [23] (for more details including
sample handling and storage, see Additional file 2).
CSF C3 and FH levels were measured using an xMAP
technology-based multiplex human neurodegenerative
kit (HNDG1-36 K; Millipore, Billercia, MA, USA) accord-
ing to the manufacturer’s overnight protocol with minor
modifications. A detailed protocol can be found on the
ADNI website [17]. Aβ1–42, t-tau and p-tau181 were
measured using the multiplex xMAP Luminex platform
(Luminex Corp, Austin, TX, USA) with an Innogenetics
kit (INNO-BIA AlzBio3; Innogenetics, Ghent, Belgium)
according to the manufacturer’s protocol [24]. CSF
hemoglobin was measured using an ELISA kit from
Bethyl Lab Inc. (Montgomery, TX, USA) according to
the manufacturer’s instructions. Rules-based medicine
(RBM; Austin, TX, USA) evaluated CSF samples using
a multiplex Human DiscoveryMAP™ panel consisting
of 159 analytes (including C3) on a Luminex 100 plat-
form (Luminex Corp, Austin, TX, USA). More details
on the methods used in the ADNI CSF Proteome study
can be found on the ADNI website [25]. For details
regarding each assay’s performance, see Additional file 2.
Magnetic resonance imaging acquisition and processing
Acquisition of 1.5-T magnetic resonance imaging (MRI)
data for the ADNI 1 subjects followed a previously de-
scribed standardized protocol that included sagittal
volumetric three-dimensional magnetization prepared
rapid acquisition gradient recalled echo (MPRAGE),
with variable resolution around the target of 1.2 mm iso-
tropically. The scans had gone through certain correction
methods such as gradwarp, B1 calibration, N3 correction
and (in-house) skull-stripping (for details see [17,26]). The
images were processed with a freely available pipeline [27]
(for software see [28]). Briefly, images were segmented
into three tissue types: grey matter, white matter andCSF. After high-dimensional image warping to an atlas,
regional volumetric maps for grey matter, white matter
and CSF were created – referred to herein as regional
volumetric analysis of brain images, which are used for
voxel-based analysis and group comparisons of regional
tissue atrophy, as well as for constructing an index of AD
brain morphology. We tested for differences in ventricular
volume in our primary analysis and for associations with
the different regions of interest in a secondary analysis.
Statistical analysis
For the analyses included in the descriptive table (Table 1),
one-way analyses of variance were used for quantitatively
normally distributed variables and the data are presented as
the mean (standard deviation). Kruskall–Wallis tests were
used for quantitative non-normally distributed variables
and the data are presented as the median (first quartile to
third quartile). Chi-square tests were applied for qualitative
variables and the data are presented as the percentage of
counts. For further analyses, distributions of the variables
and residuals were tested and power transformations
applied if necessary. C3, FH and the C3/FH ratio were
standardized to compare effect sizes across analytes.
Previous studies suggest that blood contamination of
CSF can significantly affect CSF concentrations of certain
proteins [29]. We therefore first tested whether hemoglobin
levels were associated with complement biomarker levels in
CSF, using a model that included gender, age, apolipo-
protein E epsilon 4 allele presence (APOE ε4) and clinical
diagnosis as covariates. CSF levels of FH (Figure S1a in
Additional file 3) but not of C3 were significantly associated
with hemoglobin. This association disappeared after ex-
clusion of samples with hemoglobin levels > 1,500 ng/ml
(14 CN, 24 MCI subjects, nine AD subjects) (Figure S1b
in Additional file 3). All further analyses were therefore
performed on the remaining 342 subjects. Exclusion of
the 47 subjects with high hemoglobin levels did not
significantly change the difference between diagnostic
groups for any of the variables reported in Table 1.
Associations between CSF complement biomarkers and
age, gender and APOE ε4 presence were tested in linear
regression models. FH and C3, but not C3/FH, were asso-
ciated with both age and gender. None of the CSF comple-
ment biomarkers showed a significant association with
APOE ε4 presence (Table S1 in Additional file 4).
To test the classification accuracy of the analytes, we
split the sample into a discovery set (67%) and a validation
set (33%), stratifying by clinical diagnosis. To train a classi-
fier and cross-validate the cutoff values in the discovery set,
the subjects were further randomly split 10 times to form
training (67%) versus test (33%) sets. The cutoff values of
the model were selected in the discovery set using accuracy
and the kappa index as performance metrics [30,31].
The obtained logistic regression model was then applied
Table 1 Alzheimer’s Disease Neuroimaging Initiative 1 subjects included in the study
Controls MCI subjects AD subjects P value
Number of participants
All (n = 110) (n = 187) (n = 92)
Hgb≤ 1,500 ng/ml (n = 96) (n = 163) (n = 83)
Age at baseline (years)a
All 75.4 (5.2) 74.0 (7.6) 74.4 (7.7) 0.24
Hgb≤ 1,500 ng/ml 75.6 (5.0) 74.5 (7.6) 74.8 (7.9) 0.42
Gender (% female)b
All 49.1 33.2 43.8 0.019
Hgb≤ 1,500 ng/ml 46.9 33.7 47.0 0.046
Education (years)a
All 15.7 (2.8) 15.8 (3.0) 15.0 (3.2) 0.15
Hgb≤ 1,500 ng/ml 15.8 (2.8) 15.8 (3.0) 15.1 (3.2) 0.19
MMSEa
All 29.1 (1.0) 27.0 (1.8) 23.6 (1.9) <0.0001
Hgb≤ 1,500 ng/ml 29.1 (1.0) 27.0 (1.8) 23.7 (1.9) <0.0001
ADAS-Coga
All 9.7 (4.2) 18.6 (6.7) 28.5 (8.5) <0.0001
Hgb≤ 1,500 ng/ml 9.9 (4.1) 18.7 (6.2) 28.7 (7.7) <0.0001
APOE ε4 presence (%)b
All 24.5 54.0 70.7 <0.0001
Hgb≤ 1,500 ng/ml 24.0 55.2 68.7 <0.0001
Hgb (ng/ml)c
All 42.4 (0.0 to 418.8) 24.9 (0.0 to 477.7) 87.5 (0.0 to 338.4) 0.79
Hgb≤ 1,500 ng/ml 19.6 (0.0 to 171.0) 0.64 (0.0 to 195.4) 42.9 (0.0 to 226.1) 0.40
Factor H (ng/ml)c
All 1463.5 (1132.1 to 1954.1) 1478.9 (1177.6 to 2005.5) 1660.5 (1171.4 to 2274.1) 0.26
Hgb≤ 1,500 ng/ml 1445.4 (1128.8 to 1877.1) 1452.0 (1176.3 to 1928.3) 1507.9 (1145.3 to 2053.2) 0.46
Complement 3 (ng/ml)c
All 3331.4 (2595.5 to 4743.4) 3696.0 (2658.9 to 4905.2) 3894.6 (2567.6 to 5466.0) 0.40
Hgb≤ 1,500 ng/ml 3331.4 (2644.1 to 4819.2) 3614.1 (2559.7 to 4597.7) 3690.3 (2522.3 to 5328.1) 0.73
Complement 3/factor Hc
All 2.40 (1.80 to 2.91) 2.42 (2.01 to 2.84) 2.20 (1.95 to 2.64) 0.31
Hgb≤ 1,500 ng/ml 2.41 (1.86 to 2.95) 2.41 (1.98 to 2.82) 2.26 (1.95 to 2.78) 0.55
Aβ1–42 (pg/ml)c
All 220.0 (159.0 to 253.0) 146.0 (128.0 to 202.0) 136.0 (120.8 to 160.5) <0.0001
Hgb≤ 1,500 ng/ml 220.0 (159.5 to 252.5) 146.0 (128.0 to 210.3) 137.0 (121.5 to 161.5) <0.0001
Total tau (pg/ml)c
All 61.0 (48.0 to 86.0) 87.0 (65.0 to 122.0) 110.5 (81.0 to 153.0) <0.0001
Hgb≤ 1,500 ng/ml 61.0 (48.0 to 79.5) 88.0 (65.0 to 126.0) 109.0 (77.0 to 143.0) <0.0001
p-tau181 (pg/ml)
c
All 20.0 (16.0 to 29.0) 31.5 (21.0 to 45.0) 36.0 (29.0 to 49.0) <0.0001
Hgb≤ 1,500 ng/ml 19.0 (15.0 to 26.5) 31.0 (20.5 to 45.0) 35.0 (28.0 to 46.5) <0.0001
Aβ1–42, amyloid β peptide 1–42; AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s disease Assessment Scale – cognitive subscale; APOE ε4, apolipoprotein E epsilon 4 allele;
Hgb, hemoglobin; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; p-tau181, tau phosphorylated at threonine 181.
aMean (standard deviation), P value
obtained using analysis of variance. bP value obtained using the chi-square test. cMedian (first quartile to third quartile), P value obtained using the Kruskall–Wallis test.
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area under the curve of the receiver operating characteris-
tic curve were obtained [32].
A Cox hazards model, with age, gender, t-tau/Aβ1–42
ratio, APOE ε4 presence and education as covariates was
used to study the conversion of MCI to AD for different
CSF biomarkers. Standardized values (mean = 0, standard
deviation = 1) were used for the biomarker values in order
to compare the effect size of the association.
We analyzed the cross-sectional and longitudinal as-
sociation between CSF biomarkers and different out-
come measures using mixed-effects models [33,34]. A
mixed-effects model is an extension of a linear regression
model that allows calculation of the mean trajectory of
biomarker values for each group as well as the estimation
of each patient’s trajectory. The mixed-effects model takes
into account within-subject correlations from repeated
measurements of biomarker values in the same subjects
and for missing data points. Age, gender, education, APOE
ε4 presence, t-tau/Aβ1–42 ratio and clinical diagnosis at
baseline were included as fixed effects. We include an inter-
cept, follow-up time and squared follow-up time in weeks
as random effects. Our model specified the intercept and
the regression coefficient for the follow-up time as random
effects such that subjects have a unique intercept and slope
characterizing their individual trajectories. An interaction
between time and clinical diagnosis, between time and
t-tau/Aβ1–42 ratio, and between time and the studied
CSF biomarker was also included to assess whether these
biomarkers were associated with the longitudinal change.
A significant interaction between clinical diagnosis and
time, for example, would indicate that the slope of change
during follow-up is different in CN and MCI subjects.
To plot the data we calculated the 25th, 50th and 75th
percentile biomarker values for the MCI group and esti-
mated the predicted changes based on the coefficients of
the corresponding mixed-effects model (for the variables
included in the model, median and mode values were used
for quantitative and categorical predictors).
For the MRI analysis, a mixed-effects model was
used, with a nested term inside subjects for the left and
right sides for each region of interest. Age, gender and
t-tau/Aβ1–42 ratio, clinical diagnosis and intracranial
volume were included as fixed effects.
Statistical tests were two-sided and significance was
set at P < 0.05. In the case of multiple comparisons, the
Benjamini–Hochberg correction and the Holms method
was applied when a large and lower number of com-
parisons, respectively, had been performed. Analyses
were performed using R v. 3.0.1 [35].
Results
A total of 389 ADNI 1 participants with CSF C3, FH,
Aβ1–42, t-tau and p-tau181 as well as MRI data wereincluded in the current study. Clinical and demographic
characteristics of the studied subjects are summarized in
Table 1. As expected, the clinical groups differed in gender,
MMSE, ADAS-Cog, APOE ε4 presence and CSF Aβ1–42,
t-tau and p-tau181. The data for CSF Aβ1–42, t-tau and
p-tau181 in the AD subjects are in line with published
cutoff values from autopsy confirmed cases using the
AlzBio3 kit [23]. However, no differences in CSF C3 or
FH levels or the C3/FH ratio were noted between the
diagnostic groups. As discussed earlier, all subsequent
analysis were performed on the 342 subjects whose CSF
samples had hemoglobin levels ≤ 1,500 ng/ml. Exclusion
of subjects with hemoglobin levels > 1,500 ng/ml (14 CN,
24 MCI subjects, nine AD subjects) did not seem to result
in any selection bias (Table 1).
Cross-sectional analysis
In linear regression analysis, a strong, positive correl-
ation between C3 and FH (rpartial = 0.81, P < 0.0001) was
present after adjusting for age and gender (Figure S2 in
Additional file 3). In age, gender and APOE ε4 presence
adjusted models, FH was significantly associated with t-tau
but not with p-tau181 or Aβ1–42. C3 was not associated with
Aβ1–42, t-tau or p-tau181 (Table S2 in Additional file 4).
Linear regression models adjusted for age, gender and
APOE ε4 presence revealed no association of C3, FH or
C3/FH with clinical diagnosis (Table S3 in Additional file 4).
A lack of contribution from C3 and FH in classifying
different clinical groups was further confirmed by the
fact that the addition of C3, FH or C3/FH did not im-
prove the performance of t-tau/Aβ1–42 in classifying AD
subjects versus CN or MCI subjects versus CN (Table 2).
The diagnostic utility of C3 and or FH was therefore not
evaluated further.
Finally, with regard to disease severity C3, FH and C3/
FH did not associate with baseline ADAS-cog, MMSE,
memory summary or executive function summary scores
of AD (Table 3) or MCI (Table 4) subjects in mixed-
effects models adjusted for age, gender, education, APOE
ε4 presence and t-tau/Aβ1–42 ratio.
Longitudinal analysis
Of the 160 MCI subjects included in the analysis, 79
converted to AD with a median follow-up time of
158 weeks. A Cox hazards model with age at baseline
(hazard ratio = 1.01, P = 0.59), gender (hazard ratio = 1.05,
P = 0.84), t-tau/Aβ1–42 ratio (hazard ratio = 1.49, P = 0.002),
APOE ε4 presence (hazard ratio = 1.13, P = 0.63) and edu-
cation (hazard ratio = 1.02, P = 0.70) as covariates was used
to test the association of the CSF complement biomarkers
with conversion of MCI to AD. A weak association be-
tween lower levels of C3 (hazard ratio = 0.62, Punadj = 0.046)
and increased conversion was lost after adjustment for
multiple comparisons (Padj = 0.14).
Table 2 Classification accuracy of the cerebrospinal fluid biomarkers
AD subjects vs. controls MCI subjects vs. controls
Sensitivity (%) Specificity (%) Kappa AUC Sensitivity (%) Specificity (%) Kappa AUC
Total tau/Aβ1–42 76.9 86.7 0.64 0.84 59.4 67.9 0.27 0.73
Total tau/Aβ1–42 C3 69.2 93.3 0.64 0.84 50.0 69.8 0.20 0.72
Total tau/Aβ1–42 FH 76.9 86.7 0.64 0.83 59.4 67.9 0.27 0.73
Total tau/Aβ1–42 C3/FH 76.9 86.7 0.64 0.84 56.3 66.0 0.22 0.71
Gender (male reference category) included as a covariate. Aβ1–42, amyloid β peptide 1–42; AD, Alzheimer’s disease; AUC, area under the curve; C3, complement 3;
FH, factor H; MCI, mild cognitive impairment.
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executive function summary scores were next analyzed
against baseline CSF C3 and FH levels. Follow-up of ADNI
1 patients with a baseline diagnosis of AD was discontin-
ued at an earlier time point than baseline MCI patients
(mean follow-up was 98.3 weeks for the AD group and
184 weeks for the MCI group). Owing to this imbalance
in the number of visits, we analyzed the AD subjects and
the MCI subjects separately. All of the following analyses
were adjusted for age, gender, APOE ε4 presence, edu-
cation and t-tau/Aβ1–42 ratio. In the analysis of the AD
group, none of the complement biomarkers were asso-
ciated with changes in ADAS-Cog, MMSE, memory
summary, or executive function summary scores dur-
ing follow-up (Table 3). In the MCI subjects, lower
levels of both C3 and FH were associated with an increase
(more severe cognitive impairment) in ADAS-Cog scores
during follow-up (biomarker × time interaction, Table 4;
Figure 1a,b). The C3/FH ratio showed no association
with longitudinal ADAS-Cog score changes. Finally,
none of the CSF complement biomarkers showed a sig-
nificant association with MMSE, memory summary, or
executive function summary scores, although there
was a trend for an association of lower C3 levels with a
decline in memory summary score during follow-up
(biomarker × time interaction, Table 4; Figure 1c,d,e,f ).Table 3 Association of cerebrospinal fluid complement bioma
(biomarker × time) in cognitive scores: Alzheimer’s disease su
Model Predictor ADAS-Cog M
β P value β
C3 C3 −0.0095 1.0 −0.45
C3 × time −0.0089 1.0 −0.009
FH FH −0.017 1.0 −0.14
FH × time −0.0052 1.0 −0.0072
C3/FH C3/FH 0.074 1.0 −1.25
C3/FH × time 0.014 1.0 −0.0075
Age, gender (male reference category), education, total tau/amyloid β peptide 1–42
model. P values are corrected for multiple comparisons (Holms). ADAS-Cog, Alzheim
factor H; MMSE, Mini-Mental State Examination.Correlations of complement 3 and factor H with other
ADNI variables
A subset (n = 256) of the ADNI 1 subjects included in
the study also had RBM CSF data available. The RMB
CSF panel included C3, but not FH. We explored the
association between our CSF C3 measurements and the
RBM C3 levels and found a strong correlation between
the two (r = 0.79, P < 0.0001), indicating that the two
immunoassays performed similarly. As expected, when we
repeated the diagnostic and prognostic analyses described
above using C3 levels obtained by the RBM assay, very
similar, if not identical, results were found, especially with
regard to the association between lower levels of C3 and
faster cognitive decline of MCI subjects.
Since brain atrophy detected by MRI is associated with
AD severity and correlates closely with changes in cognitive
performance [36], we also studied the association between
the CSF complement biomarkers and MRI volumes at
baseline in a model adjusted for age, gender, clinical diagno-
sis, t-tau/Aβ1–42 ratio and intracranial volume. There were
no associations between C3 levels or the C3/FH ratio and
MRI volumes. However, although no association with CSF
FH levels was noted when different region of interest were
analyzed independently (Table S4 in Additional file 4), low
FH values were clearly associated with increased lateral
ventricular volume in the multiple comparison-adjustedrkers with baseline and longitudinal changes
bjects
MSE Memory Executive
P value β P value β P value
0.53 0.10 0.76 −0.061 1.0
1.0 0.085 0.18 0.12 0.092
0.54 0.083 0.59 −0.057 1.0
1.0 0.048 0.18 0.072 0.085
0.51 −0.074 0.78 0.095 1.0
1.0 0.092 0.42 0.081 0.57
ratio and apolipoprotein E epsilon 4 allele presence adjusted mixed-effects
er’s disease Assessment Scale – cognitive subscale; C3, complement 3; FH,
Table 4 Association of cerebrospinal fluid complement biomarkers with baseline and longitudinal changes
(biomarker × time) in cognitive scores: mild cognitive impairment subjects
Model Predictor ADAS-Cog MMSE Memory Executive function
β P value β P value β P value β P value
C3 C3 −0.061 1.0 −0.062 1.0 −0.050 1.0 0.20 0.18
C3 × time −0.12 0.041 0.40 0.16 0.067 0.051 0.028 0.70
FH FH −0.077 1.0 −0.17 1.0 −0.014 1.0 0.077 0.29
FH × time −0.075 0.041 0.29 0.15 0.037 0.089 0.26 0.51
C3/FH C3/FH 0.076 1.0 0.49 1.0 −0.13 1.0 0.41 0.18
C3/FH × time −0.18 0.057 0.34 0.44 0.10 0.089 −0.0013 0.98
Age, gender (male reference category), education, total tau/amyloid β peptide 1–42 ratio and apolipoprotein E epsilon 4 allele presence adjusted mixed-effects
model. P values are corrected for multiple comparisons (Holms). ADAS-Cog, Alzheimer’s disease Assessment Scale – cognitive subscale; C3, complement 3; FH,
factor H; MMSE, Mini-Mental State Examination.
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low CSF FH level is associated with greater brain atrophy.
Discussion
In this study, we explored the diagnostic and prognostic
value of CSF C3 and FH levels in AD and MCI. In
cross-sectional analysis, there were no significant dif-
ferences in either biomarker or in their ratio between
diagnostic groups, and nor were there any correlations
with disease severity in AD or MCI subjects as measured
by the MMSE, ADAS-Cog, memory summary score or
executive function summary score. In the longitudinal
analysis of MCI patients, however, low levels of both C3
and FH were modestly associated with an increase in
ADAS-Cog scores (more severe cognitive impairment)
and validation in an independent and longitudinal cohort
is needed. Additionally, there was a significant association
of low CSF FH levels with increased lateral ventricularFigure 1 Association of cerebrospinal fluid complement 3 and factor
impairment subjects. (a), (b) Alzheimer’s disease Assessment Scale – cog
(f) summary executive function scores are represented on the y axis, with foll
treated as quantitative in the analysis, the graphs represent the different tertilvolume, which is indicative of brain atrophy and has been
shown to correlate strongly with changes in cognitive tests
[37]. Strengths of the current study include the use of a
large cohort of subjects that underwent detailed clinical
and neuropsychological testing and longitudinal follow-
up, the availability of APOE ε4 genotype data, hemoglobin
measurements to control for blood contamination of CSF,
as well as the use of RBM CSF C3 data to corroborate our
own measurements and results.
Previous studies have generally reported elevated levels
of complement components in AD CSF, although results
are inconsistent. For example, in a recent study [38]
using a commercially available ELISA kit, CSF C3 levels
were increased in AD patients and CN subjects com-
pared with stable MCI subjects, but there was no signifi-
cant difference between AD patients and CN subjects,
or between the MCI-to-AD group and any of the other
groups. Consistent with the current finding, receiverH levels with longitudinal cognitive changes in mild cognitive
nitive subscale (ADAS-Cog), (c), (d) summary memory scores and (e),
ow-up time on the x axis. Although the variables examined here were
es for ease of visual representation. C3, complement 3; FH, factor H.
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utility for CSF C3. On the other hand, in a study using
the RBM Human DiscoveryMAP™ panel on a Luminex
100 platform, CSF C3 levels were increased in autopsy-
confirmed AD cases compared with normal controls.
Furthermore, there was a significant correlation between
CSF C3 levels and MMSE scores in AD subjects, but not
in MCI subjects [39]. In contrast, a study using two-
dimensional electrophoresis found no significant differ-
ence in the average percent volume for C3b or FH in
CSF samples from AD compared with normal controls
[40]. In line with the RBM study discussed above, our
own earlier study found increased CSF C3 and FH levels
in AD patients compared with CN subjects, as well as
significant negative correlations between the two com-
plement biomarkers and MMSE scores [41]. The failure
to validate our own earlier findings in the current study
may be related to differences between the two cohorts,
including highly selected subjects in the ADNI versus
the community-based cohort in our previous study, gen-
der distribution and mean age, as well as the number of
AD patients included in the analysis (38 in the previous
study vs. 83 in the current study). One should also point
out that although our original study found significant
differences in CSF C3 and FH levels between diagnostic
groups, receiver operating characteristic analysis showed
that neither biomarker had acceptable sensitivity or spe-
cificity (>60%) for classifying CN versus AD subjects. In
summary, we conclude that these studies are in agree-
ment regarding a lack of suitability of CSF C3 and FH as
diagnostic biomarkers of AD.
A limitation of our investigation is the potential con-
founding effect of pharmacotherapy, because subjects
were not drug naïve at the time of CSF collection, although
the use of many central nervous system-active drugs such
as antidepressants or neuroleptics with anti-cholinergic
properties, narcotic analgesics and anti-Parkinsonian
medications were excluded. The other limitation relates
to the fact that the data are correlational without clear
mechanistic interpretation. That said, we wish to put
forward two hypotheses for discussion. First, our finding
of low levels of CSF C3 and FH in MCI patients with ac-
celerated cognitive decline may reflect increased depos-
ition of these complement biomarkers in senile plaques.
Decreased Aβ1–42 in AD CSF is hypothesized to be the
result of trapping the peptide in plaques, and C3 and
FH have both been shown to be present in Aβ plaques
[11,42,43]. Trapping of C3 and FH in plaques may therefore
lead to a decrease in the CSF levels of these proteins. How-
ever, we did not find a correlation between CSF Aβ1–42 and
C3 or FH, suggesting that the observed decrease in comple-
ment biomarkers cannot be readily explained by such a
simplistic model. An alternative hypothesis could there-
fore be that the low CSF levels of C3 and FH in fasterprogressors may reflect accelerated dysregulation of the
complement system in the brain. To this end, many
studies have indicated potential involvement of comple-
ment system in AD pathogenesis, including observations
that: Aβ fibrils activate both the classical and alternative
complement pathways in vitro [44-46]; inhibition of C3 in a
mouse model of AD resulted in accelerated and increased
Aβ plaque deposition, as well as neurodegeneration
[47-49]; and AD mice lacking C1q (part of the complex
triggering activation of the classical pathway) had decreased
levels of activated glia in proximity to plaques, as well as re-
duced neuronal injury [50] consistent with a detrimental
role for complement activation in this model. Indeed, based
on these and other studies, a hypothesis has been suggested
that classical complement activation is detrimental in neu-
rodegeneration, whereas alternative complement activation
is beneficial up to a certain threshold or depending on
the complement receptor CR1 genotype [51]. Thus, if
CSF levels of C3 and FH mirror their levels in the brain,
our finding of a decreased total C3 level may indicate in-
creased cleavage of C3 to generate more of its active frag-
ments at the expense of the holoprotein. This increased
activation of C3 might be due to increased activation of
the classical, lectin and/or alternative pathways, as C3 is a
joining point for all three. Decreased levels of FH will also
lead to increased cleavage of C3 via the alternative path-
way, because FH regulates this pathway at the C3 conver-
tase level [9]. The strong correlation observed between
CSF C3 and FH in the current study supports this hypoth-
esis. The negative finding with regard to the longitudinal
analysis in AD patients could be secondary to the much
shorter followup in these patients and a smaller sample
size, which results in less statistical power.Conclusions
In summary, our data suggest that CSF C3 and FH levels
are prognostic biomarkers of accelerated cognitive decline
in MCI, although validation in an independent cohort is
needed. Additionally, studies with repeated CSF measure-
ments will shed more light on the utility of CSF C3 and
FH levels as AD progression biomarkers. Finally, results
obtained in this study should encourage further investiga-
tions exploring the mechanisms underlying complement
activation, both the classical and alternative cascades, in
AD development and progression.Additional files
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